CN110251523A - 一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂 - Google Patents
一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂 Download PDFInfo
- Publication number
- CN110251523A CN110251523A CN201910460408.XA CN201910460408A CN110251523A CN 110251523 A CN110251523 A CN 110251523A CN 201910460408 A CN201910460408 A CN 201910460408A CN 110251523 A CN110251523 A CN 110251523A
- Authority
- CN
- China
- Prior art keywords
- acid
- synergist
- preparation
- glucuronic acid
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 title claims abstract description 20
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229940097043 glucuronic acid Drugs 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 208000007443 Neurasthenia Diseases 0.000 abstract description 4
- 206010003549 asthenia Diseases 0.000 abstract description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical class NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂。其是由谷氨酰胺、天门冬氨酸、左旋肉碱、磷脂酰胆碱和葡萄糖醛酸组成，葡萄糖醛酸作为增效剂。用以口服，提高目标人群或个体的注意力，缓解神经衰弱。具有依赖性低、起效快、使用安全的特点。
Description
技术领域
本发明公开了一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂。其是由谷氨酰胺、天门冬氨酸、左旋肉碱、磷脂酰胆碱和葡萄糖醛酸组成，葡萄糖醛酸作为增效剂。用以口服，提高目标人群或个体的注意力，缓解神经衰弱。具有依赖性低、起效快、使用安全的特点。本发明属于药品加工领域。
背景技术
生活中人们往往关注记忆力，而忽略注意力。特别是当儿童大脑神经系统兴奋和抑制过程发育不平衡，前庭觉信息处理不良时，导致儿童的持续注意时间较短、对事物不感兴趣、情绪急躁易怒、独立思考能力减弱，严重者会出现多动症。目前，对儿童注意力集中问题采用的大多仍是物理的注意力训练法，方法费时费力。注意力主要为视觉引起的对某种事物的持续生理活动，加上听觉、味觉共同构成人及其他高等动物的专注度。有研究表明，脑活动主要由兴奋性神经递质如谷氨酸、天冬氨酸等和抑制性神经递质如γ-氨基丁酸的协同作用完成。有研究产品在学生群体中使用氨基酸营养液进行输液，目前其效果不能肯定，且存在感染风险。还有利用多巴胺类或氨茶碱类及其效应类似物制备所谓“聪明药”，存在人体形成依赖性问题。实践表明，所谓摄食蔗糖、牛奶、咖啡等提高注意力并不是有效措施。
神经衰弱的症状常常出现在部分应考的学生和工作压力大的中年群体中。神经衰弱与注意力低的区别在于前者是专注度的衰减，后者是注意力转移。
研究表明，谷氨酸、天门冬氨酸、谷氨酰胺等氨基酸类物质能够转化为中枢递质，或直接参与脑神经活动，调节体内及脑神经递质多巴胺、去甲肾上腺素、乙酰胆碱酯酶和5-羟色胺的活性。左旋肉碱和磷脂酰胆碱能够促进细胞膜氨基酸、信息物质和能量的转运。葡萄糖醛酸能够辅助体内代谢废物排出，促进碱性基团物质吸收。本发明采用葡糖醛酸为增效剂，配以体内天然存在氨基酸及其衍生物和两种碱性成分，配制成口服制剂，用以提高目标人群或个体的注意力及专注度，缓解神经衰弱。
发明内容
本发明的目的是提供一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂。该制剂口服后能够提高目标人群或个体的注意力，缓解神经衰弱，本发明的目的是通过以下的技术方法来实现的：
A、选用谷氨酰胺、天门冬氨酸、左旋肉碱、磷脂酰胆碱和葡糖糖醛酸作为原料；
B、原料按比例混合组成口服制剂；
A中所述的选用谷氨酰胺、天门冬氨酸、左旋肉碱、磷脂酰胆碱和葡萄糖醛酸作为原料，其原料葡萄糖醛酸作为增效剂。与葡萄糖醛酸具有部分相似结构和增效能力的葡萄糖、甘露糖、半乳糖及其醛酸、甘露醇、柠檬酸也可部分替代或辅助葡萄糖醛酸增效；
B中所述的原料按比例混合组成口服制剂，其比例为谷氨酰胺:天门冬氨酸:左旋肉碱:磷脂酰胆碱:葡糖糖醛酸约等于1:1:2:1:5，且每种原料的比例可上浮或下浮50%；
B中所述的原料按比例混合组成口服制剂，其制剂包括粉剂、颗粒剂、丸剂、片剂、胶囊剂。
具体实施方式
以下实施例用于说明本发明，使其更明确，但决不用来限制本发明的范围，实施例1：
1）谷氨酰胺0.1 g、天门冬氨酸0.1 g、左旋肉碱0.2 g、磷脂酰胆碱0.1 g、葡糖醛酸0.4g，混合，再与0.9 g淀粉和0.2 g蜂蜜混合制成丸剂。
Claims (5)
1.一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂，其制剂的制备在于以下步骤：
A、选用谷氨酰胺、天门冬氨酸、左旋肉碱、磷脂酰胆碱和葡糖糖醛酸作为原料；
B、原料按比例混合组成口服制剂。
2.权利要求1A中所述的选用谷氨酰胺、天门冬氨酸、左旋肉碱、磷脂酰胆碱和葡萄糖醛酸作为原料，其原料葡萄糖醛酸作为增效剂。
3.权利要求2中所述的其原料葡萄糖醛酸作为增效剂，其增效剂包括与葡萄糖醛酸具有部分相似作用的葡萄糖、甘露糖、半乳糖及其醛酸、甘露醇、柠檬酸。
4.权利要求1B中所述的原料按比例混合组成口服制剂，其比例为谷氨酰胺:天门冬氨酸:左旋肉碱:磷脂酰胆碱:葡糖糖醛酸约等于1:1:2:1:5，且每种原料的比例可上浮或下浮50%。
5.权利要求1B中所述的原料按比例混合组成口服制剂，其制剂包括粉剂、颗粒剂、丸剂、片剂、胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910460408.XA CN110251523A (zh) | 2019-05-30 | 2019-05-30 | 一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910460408.XA CN110251523A (zh) | 2019-05-30 | 2019-05-30 | 一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110251523A true CN110251523A (zh) | 2019-09-20 |
Family
ID=67915944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910460408.XA Pending CN110251523A (zh) | 2019-05-30 | 2019-05-30 | 一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110251523A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996008238A1 (en) * | 1994-09-14 | 1996-03-21 | Glaxo Group Limited | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists |
| CN101946945A (zh) * | 2010-08-26 | 2011-01-19 | 李健光 | 左旋肉碱水饮料 |
-
2019
- 2019-05-30 CN CN201910460408.XA patent/CN110251523A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996008238A1 (en) * | 1994-09-14 | 1996-03-21 | Glaxo Group Limited | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists |
| CN101946945A (zh) * | 2010-08-26 | 2011-01-19 | 李健光 | 左旋肉碱水饮料 |
Non-Patent Citations (2)
| Title |
|---|
| 周旭波等: "氨基酸保健品的现状及发展趋势", 《氨基酸和生物资源》 * |
| 苏玉芳等: "添加大豆磷脂酰胆碱的奶粉对小鼠记忆力的影响", 《中国乳品工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101889679B (zh) | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 | |
| KR101735151B1 (ko) | 항피로 조성물, 그의 제형 및 용도 | |
| CN102389116A (zh) | 一种能够缓解体力疲劳的泡腾片及其制备工艺 | |
| CN104173407B (zh) | 一种牛蒡低聚糖泡腾片及其制备方法 | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN101485445A (zh) | 保健食品 | |
| JP2006187258A (ja) | パン酵母由来のβ−グルカンを含有する免疫力改善食品 | |
| CN102210474A (zh) | 一种护眼健脑泡腾片剂 | |
| CN109619249A (zh) | 一种藻油dha加锌凝胶糖果及其制备方法 | |
| CN102160664A (zh) | 儿童营养饮料 | |
| CN104721181A (zh) | 二氢杨梅素在制备促进睡眠、改善睡眠质量制剂的用途 | |
| CN104757560A (zh) | 一种谷胱甘肽酵母酶解组合物及其制备方法 | |
| US20150147418A1 (en) | Sleep quality improving agent | |
| CN103445175A (zh) | 具有解酒保肝作用的组合物 | |
| CN103284261A (zh) | 一种含有巴戟天的运动饮料及其制备方法 | |
| CN104644734B (zh) | 一种治疗ⅱ型糖尿病及其并发症的药物 | |
| CN110251523A (zh) | 一种以葡萄糖醛酸为增效剂的能够强化注意力且缓解神经衰弱的制剂 | |
| JP2014172892A (ja) | 睡眠改善剤、ノンレム睡眠時間増加剤及び鎮静剤 | |
| CN102335251A (zh) | 一种具有解酒功能的组合物及其制备方法 | |
| CN103271353B (zh) | 一种护肝保健组合物及其制备方法 | |
| CN104435100A (zh) | 一种抗抑郁组合物 | |
| CN114916604A (zh) | 一种具有保健功能的凝胶糖果 | |
| CN101491668B (zh) | 一种具有降血糖功能的组合物及其制备方法 | |
| US20120129803A1 (en) | Composition containing chitooligosaccharide for recovering from fatigue | |
| JP2007008866A (ja) | 血圧降下剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |